Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:BMED NYSEARCA:CLIA NYSEARCA:KBUF NYSEARCA:THNR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEDiShares Health Innovation Active ETF$26.12+0.5%$25.19$20.57▼$27.02$4.18M0.771,813 shs458 shsCLIAVeridien Climate Action ETF$18.61-0.2%$18.61$16.48▼$21.28$23.45M1.349,925 shs75,500 shsKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETF$32.41+0.7%$31.33$24.76▼$32.56$3.89M0.641,498 shs204 shsTHNRAmplify Weight Loss Drug & Treatment ETF$22.92+0.7%$22.83$18.56▼$28.19$2.98MN/A2,052 shs2,422 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEDiShares Health Innovation Active ETF0.00%-0.72%+5.71%+8.43%-0.38%CLIAVeridien Climate Action ETF0.00%0.00%0.00%0.00%0.00%KBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETF0.00%-0.31%+4.11%+8.36%+25.57%THNRAmplify Weight Loss Drug & Treatment ETF0.00%-0.99%+2.09%+3.43%-17.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEDiShares Health Innovation Active ETFN/AN/AN/AN/AN/AN/AN/AN/ACLIAVeridien Climate Action ETFN/AN/AN/AN/AN/AN/AN/AN/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETFN/AN/AN/AN/AN/AN/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEDiShares Health Innovation Active ETF 2.76Moderate Buy$26.12N/ACLIAVeridien Climate Action ETF 2.50Hold$18.61N/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETF 0.00N/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETF 2.57Moderate Buy$22.92N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEDiShares Health Innovation Active ETFN/AN/AN/AN/AN/AN/ACLIAVeridien Climate Action ETFN/AN/AN/AN/AN/AN/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETFN/AN/AN/AN/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEDiShares Health Innovation Active ETFN/AN/A24.91∞N/AN/AN/AN/AN/ACLIAVeridien Climate Action ETFN/AN/A16.68∞N/AN/AN/AN/AN/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETFN/AN/A16.82∞N/AN/AN/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AN/A24.31∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEDiShares Health Innovation Active ETFN/AN/AN/AN/AN/ACLIAVeridien Climate Action ETFN/AN/AN/AN/AN/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETF$0.983.02%N/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETF$0.220.96%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEDiShares Health Innovation Active ETFN/ACLIAVeridien Climate Action ETFN/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETFN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AInsider OwnershipCompanyInsider OwnershipBMEDiShares Health Innovation Active ETFN/ACLIAVeridien Climate Action ETFN/AKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETFN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEDiShares Health Innovation Active ETFN/A160,000N/ANot OptionableCLIAVeridien Climate Action ETFN/A1.26 millionN/ANot OptionableKBUFKraneShares 90% KWEB Defined Outcome Through January 2026 ETFN/A120,000N/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/A130,000N/AN/ACLIA, THNR, BMED, and KBUF HeadlinesRecent News About These CompaniesWeight Loss Drug ETF (THNR) Hits New 52-Week HighJune 2, 2025 | zacks.comNew Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFsJanuary 17, 2025 | etftrends.comEDisruptive Theme of the Week – Breakthroughs in MedicineNovember 21, 2024 | etftrends.comEAmplify ETFs Hits $10 Billion in Assets Amid New ETF LaunchesOctober 29, 2024 | etftrends.comETap the Weight-Loss Drug Market With These ETFsSeptember 18, 2024 | zacks.comDisruptive Theme of the Week: Playing DefenseAugust 14, 2024 | etftrends.comEETFs in Focus as Competition Heats Up in Weight Loss Drug SegmentJuly 22, 2024 | zacks.comTop Themes in the First Half of 2024: Crypto, Chips, Ships & SilverJuly 2, 2024 | etftrends.comEWhy Investors Haven't Feasted on Two New Weight-Loss ETFsJune 24, 2024 | investopedia.comFinding Opportunity in Unloved Healthcare ETFsMay 31, 2024 | etftrends.comEPlay These New ETFs to Tap Lucrative Weight Loss Drug MarketMay 22, 2024 | zacks.comMedia Sentiment Over TimeCLIA, THNR, BMED, and KBUF Company DescriptionsiShares Health Innovation Active ETF NYSEARCA:BMED$26.12 +0.12 (+0.46%) As of 08/29/2025 04:10 PM EasternThe BlackRock Future Health ETF (BMED) is an exchange-traded fund that is based on the MSCI All Country World index. The fund is actively managed to invest in global equities in the health sciences industry. BMED was launched on Sep 29, 2020 and is managed by BlackRock.Veridien Climate Action ETF NYSEARCA:CLIA$18.61 -0.04 (-0.21%) As of 08/16/2024The Veridien Climate Action ETF (CLIA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed, non-transparent ETF that seeks to invest in companies, via US-listed stocks or ADRs from around the world, that are considered to be making a substantial contribution to mitigating climate change. The fund utilizes the Precidian non-transparent model CLIA was launched on May 8, 2023 and is managed by Veridien.KraneShares 90% KWEB Defined Outcome Through January 2026 ETF NYSEARCA:KBUF$32.41 +0.22 (+0.68%) As of 08/29/2025 04:10 PM EasternThe KraneShares 90% KWEB Defined Outcome January 2026 ETF (KBUF) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund seeks to track the total return of the KraneShares CSI China Internet ETF (KWEB) up to a cap, with a 90% downside hedge over a two-year outcome period. The actively managed fund holds shares of the underlying ETF and options to obtain exposure. KBUF was launched on Feb 8, 2024 and is issued by KraneShares.Amplify Weight Loss Drug & Treatment ETF NYSEARCA:THNR$22.92 +0.16 (+0.70%) As of 08/29/2025 04:10 PM EasternThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
